Aliases & Classifications for Type I

MalaCards integrated aliases for Type I:

Name: Type I 76

Summaries for Type I

MalaCards based summary : Type I is related to osteogenesis imperfecta, type viii and limbal stem cell deficiency. An important gene associated with Type I is COL1A1 (Collagen Type I Alpha 1 Chain), and among its related pathways/superpathways are Developmental Biology and Cytoskeletal Signaling. The drugs Felodipine and Zinc have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Glutaric acidemia type 1 (or \"glutaric aciduria\", \"GA1\", or \"GAT1\") is an inherited disorder in... more...

Related Diseases for Type I

Diseases related to Type I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1468)
# Related Disease Score Top Affiliating Genes
1 osteogenesis imperfecta, type viii 32.7 COL1A1 COL1A2
2 limbal stem cell deficiency 29.9 KRT13 KRT14 KRT19
3 basal cell carcinoma 29.5 KRT14 KRT16 KRT17 KRT19
4 papilloma 29.3 IFNAR1 KRT13 KRT14
5 glossitis 29.2 KRT16 KRT17
6 spinal muscular atrophy, type i 12.3
7 tyrosinemia, type i 12.3
8 3-methylglutaconic aciduria, type i 12.3
9 trichorhinophalangeal syndrome, type i 12.3
10 corneal dystrophy, lattice type i 12.3
11 dentin dysplasia, type i 12.2
12 osteogenesis imperfecta, type i 12.2
13 usher syndrome, type i 12.2
14 chiari malformation type i 12.2
15 microcephalic osteodysplastic primordial dwarfism, type i 12.2
16 thanatophoric dysplasia, type i 12.2
17 schindler disease, type i 12.2
18 bare lymphocyte syndrome, type i 12.2
19 xanthinuria, type i 12.2
20 plasminogen deficiency, type i 12.2
21 porphyria cutanea tarda, type i 12.2
22 gaucher disease, type i 12.1
23 multiple endocrine neoplasia, type i 12.1
24 angioedema, hereditary, type i 12.1
25 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 12.1
26 neurofibromatosis, type i 12.1
27 pseudohypoaldosteronism, type i, autosomal recessive 12.1
28 gm1-gangliosidosis, type i 12.1
29 corticosterone methyloxidase type i deficiency 12.1
30 pseudohypoaldosteronism, type i, autosomal dominant 12.1
31 complement component 8 deficiency, type i 12.1
32 hyperoxaluria, primary, type i 12.1
33 albinism, ocular, type i 12.1
34 corneal dystrophy, groenouw type i 12.1
35 hyperlysinemia, type i 12.0
36 crigler-najjar syndrome, type i 12.0
37 opitz gbbb syndrome, type i 12.0
38 congenital disorder of glycosylation, type i/iix 12.0
39 hyperlipoproteinemia, type i 12.0
40 atelosteogenesis, type i 12.0
41 otopalatodigital syndrome, type i 12.0
42 leydig cell hypoplasia, type i 12.0
43 stickler syndrome, type i 12.0
44 persistent mullerian duct syndrome, types i and ii 12.0
45 hyperprolinemia, type i 11.9
46 leukocyte adhesion deficiency, type i 11.9
47 camptodactyly syndrome, guadalajara, type i 11.9
48 autosomal recessive cutis laxa type i 11.9
49 cockayne syndrome type i 11.9
50 hereditary antithrombin deficiency type i 11.9

Graphical network of the top 20 diseases related to Type I:



Diseases related to Type I

Symptoms & Phenotypes for Type I

GenomeRNAi Phenotypes related to Type I according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.31 ACVR1B PRKAR1A ACVR1C TGFBR1 ACVRL1
2 Decreased viability GR00221-A-2 10.31 ACVR1B PRKAR1A ACVRL1 PIP5K1C
3 Decreased viability GR00221-A-3 10.31 PRKAR1A ACVRL1
4 Decreased viability GR00221-A-4 10.31 PRKAR1A ACVR1B ACVR1C TGFBR1 ACVRL1 ACVR1
5 Decreased viability GR00402-S-2 10.31 ACVR1B PRKAR1A ACVR1C TGFBR1 ACVRL1 ACVR1
6 Increased cell viability after pRB stimulation GR00230-A-1 8.92 ACVR1C ACVRL1 ACVR1 ACVR1B

MGI Mouse Phenotypes related to Type I:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 COL1A1 ACVR1B COL1A2 ACVRL1 ACVR1 KRT16
2 cellular MP:0005384 10.35 COL1A1 ACVR1B COL1A2 ACVR1 KRT16 IL1R1
3 mortality/aging MP:0010768 10.3 ACVR1B COL1A2 ACVR1C ACVRL1 ACVR1 COL1A1
4 cardiovascular system MP:0005385 10.25 ACVR1 COL1A1 ACVRL1 IFNAR1 IL1R1 COL1A2
5 digestive/alimentary MP:0005381 10.25 COL1A1 ACVR1B ACVRL1 ACVR1 KRT16 KRT17
6 homeostasis/metabolism MP:0005376 10.25 COL1A1 ACVR1B COL1A2 ACVRL1 ACVR1 IFNAR1
7 integument MP:0010771 10.25 ACVR1B COL1A2 COL1A1 KRT16 IL1R1 KRT17
8 craniofacial MP:0005382 10.18 COL1A1 ACVR1B ACVRL1 ACVR1 KRT16 IL1R1
9 embryo MP:0005380 10.15 COL1A1 ACVR1B ACVRL1 ACVR1 KRT18 PRKAR1A
10 endocrine/exocrine gland MP:0005379 10.13 COL1A1 ACVR1B KRT14 IFNAR1 IL1R1 PRKAR1A
11 neoplasm MP:0002006 9.91 COL1A1 ACVR1 IFNAR2 IL1R1 KRT14 IFNAR1
12 muscle MP:0005369 9.87 ACVR1 COL1A1 ACVRL1 IL1R1 COL1A2 PRKAR1A
13 normal MP:0002873 9.85 COL1A1 ACVR1B ACVR1C COL1A2 ACVRL1 IL1R1
14 respiratory system MP:0005388 9.5 COL1A1 ACVR1B ACVRL1 KRT14 IL1R1 PRKAR1A
15 skeleton MP:0005390 9.28 ACVR1 COL1A1 ACVR1B IFNAR1 IL1R1 COL1A2

Drugs & Therapeutics for Type I

Drugs for Type I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Felodipine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72509-76-3 3333
2
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
4
Spironolactone Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 1952-01-7, 52-01-7 5833
5
Tazobactam Approved Phase 4,Phase 1 89786-04-9 123630
6
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
7
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
8
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
9
Furosemide Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54-31-9 3440
10
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
11
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 88150-42-9 2162
12
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79902-63-9 54454
13
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
14
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
15
Amiloride Approved Phase 4,Phase 3,Not Applicable 2016-88-8, 2609-46-3 16231
16
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2 274901-16-5 6918537
17
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
18
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
19
Ramipril Approved Phase 4,Phase 3,Phase 2,Phase 1 87333-19-5 5362129
20
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14636-12-5 72081
21
Bupivacaine Approved, Investigational Phase 4,Phase 2 2180-92-9, 38396-39-3 2474
22
Doxazosin Approved Phase 4,Not Applicable 74191-85-8 3157
23
Clonidine Approved Phase 4,Phase 3,Phase 1,Early Phase 1 4205-90-7 2803
24
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
25
Allopurinol Approved Phase 4,Phase 3,Phase 2 315-30-0 2094
26
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
27
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
28
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
29
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 76420-72-9 6917719
30 Lacidipine Approved, Investigational Phase 4,Phase 1 103890-78-4
31
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137862-53-4 60846
32
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 118072-93-8 68740
33
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73590-58-6 4594
34
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
35
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 52232-67-4 16133850
36
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
37
Cilnidipine Approved, Investigational Phase 4,Phase 3,Phase 1 132203-70-4 5282138
38
Ofloxacin Approved Phase 4 82419-36-1 4583
39
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
40
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
41
Succinylcholine Approved Phase 4 306-40-1 5314
42
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 75847-73-3 5362032 40466924
43
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 6740-88-1 3821
44
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 30516-87-1 35370
45
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
46
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
47
Diazoxide Approved Phase 4 364-98-7 3019
48
Bisoprolol Approved Phase 4,Phase 2,Phase 3,Not Applicable 66722-44-9 2405
49
Finasteride Approved Phase 4 98319-26-7 57363
50
Lercanidipine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 100427-26-7 65866

Interventional clinical trials:

(show top 50) (show all 5780)
# Name Status NCT ID Phase Drugs
1 The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes Unknown status NCT02307695 Phase 4 Saxagliptin;Insulin
2 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
3 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
5 Microalbuminuria and Allopurinol in Type 1 Diabetes Unknown status NCT02829177 Phase 4 Allopurinol;Placebo
6 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
7 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
8 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
9 GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients Unknown status NCT01592279 Phase 4 liraglutide;Insulin injections
10 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Unknown status NCT01848990 Phase 4 Commercial Hylenex® recombinant (hyaluronidase human injection);Precommercial Hylenex recombinant (hyaluronidase human injection);Insulin lispro;Insulin aspart;Insulin glulisine
11 Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy Unknown status NCT00328302 Phase 4 Candesartan;Placebo
12 Dapagliflozin in Type 1 Diabetes Unknown status NCT02211742 Phase 4 Dapagliflozin
13 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
14 Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
15 Obtain a Good Blood Glucose Control With the Paradigm Real Time System Unknown status NCT00441129 Phase 4
16 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4 Diazoxide;Placebo
17 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
18 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
19 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
20 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
21 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
22 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
23 Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs Unknown status NCT00192803 Phase 4 candesartan
24 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
25 Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Unknown status NCT01902186 Phase 4 raltegravir and atazanavir and ritonavir;tenofovir/emtricitabine and atazanavir and ritonavir
26 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
27 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
28 The Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section Unknown status NCT02504749 Phase 4
29 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
30 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
31 Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture Unknown status NCT00829725 Phase 4
32 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
33 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
34 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
35 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
36 A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes Unknown status NCT00144144 Phase 4 Angiotensin II receptor antagonists, Calcium channel blocker
37 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
38 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Unknown status NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
39 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
40 ASCEND: A Study of Cardiovascular Events iN Diabetes Unknown status NCT00135226 Phase 4 aspirin;Omega-3-acid Ethyl Esters;Placebo Aspirin;Placebo omega-3-Ethyl Esters
41 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Unknown status NCT02572960 Phase 4 Valsartan;Placebo Valsartan
42 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
43 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4 Candesartan
44 The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
45 The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients Unknown status NCT01305850 Phase 4 placebo;Aliskiren;Aliskiren plus Losartan;Enalapril plus Losartan
46 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
47 Irbesartan and Adhesion Molecules in AF Unknown status NCT00613496 Phase 4 irbesartan;placebo
48 Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody Unknown status NCT00360763 Phase 4 candesartan cilexetil
49 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
50 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan

Search NIH Clinical Center for Type I

Genetic Tests for Type I

Anatomical Context for Type I

MalaCards organs/tissues related to Type I:

41
Bone, T Cells, Heart, Kidney, Testes, Pancreas, Brain

Publications for Type I

Articles related to Type I:

(show top 50) (show all 7351)
# Title Authors Year
1
Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers. ( 29952249 )
2018
2
Aberrant activation of type I interferon system may contribute to the pathogenesis of anti-MDA5 dermatomyositis. ( 29947075 )
2018
3
A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type <i>C. elegans</i>. ( 29928508 )
2018
4
Nontypeable Haemophilus influenzae DNA stimulates type I interferon expression via STING signaling pathway. ( 29421524 )
2018
5
Relationship of Morphologic Changes in the Brain and Spinal Cord and Disease Symptoms with Cerebrospinal Fluid Hydrodynamic Changes in Patients with Chiari Malformation Type I. ( 29803060 )
2018
6
Spinning, hurting, still, afraid: Living life spaces with Type I Chiari Malformation. ( 29395547 )
2018
7
Rapid progression and mortality of necrotizing fasciitis caused by Aeromonas hydrophila in a patient with type I open tibial fracture. ( 29699639 )
2018
8
Protein-restricted maternal diet during lactation decreases type I and type III tropocollagen synthesis in the skin of mice offspring. ( 29961398 )
2018
9
Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm. ( 29755702 )
2018
10
Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state. ( 29444943 )
2018
11
Novel Assessment of Cerebrospinal Fluid Dynamics by Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging in Patients with Chiari Malformation Type I. ( 29325958 )
2018
12
Gauchera89s disease Type I: a case report ( 29756427 )
2018
13
Delayed neurological deterioration following atlantoaxial facet joint distraction and fixation in a patient with Chiari malformation type I. ( 29303466 )
2018
14
Rubus idaeus L. (red raspberry) blocks UVB-induced MMP production and promotes type I procollagen synthesis via inhibition of MAPK/AP-1, NF-I_I^ and stimulation of TGF-I^/Smad, Nrf2 in normal human dermal fibroblasts. ( 29966991 )
2018
15
Morphometric and volumetric comparison of 102 children with symptomatic and asymptomatic Chiari malformation Type I. ( 29125445 )
2018
16
Basophils activated via TLR signaling may contribute to pathophysiology of type I autoimmune pancreatitis&amp;quot;. ( 29663078 )
2018
17
PHD2 inactivation in Type I cells drives HIF-2I+ dependent multi-lineage hyperplasia and the formation of paraganglioma-like carotid bodies. ( 29917232 )
2018
18
Human Cytomegalovirus Tegument Protein pp65 (pUL83) Dampens Type I Interferon Production by Inactivating the DNA Sensor cGAS without Affecting STING. ( 29263269 )
2018
19
Type I Chiari Malformation Presenting in an Adult. ( 29895578 )
2018
20
Dentin dysplasia type I-A dental disease with genetic heterogeneity. ( 29575674 )
2018
21
A Novel FOXL2 Mutation Implying Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome Type I. ( 29339661 )
2018
22
Wireless peripheral nerve stimulation for complex regional pain syndrome type I of the upper extremity: a case illustration introducing a novel technology. ( 29794269 )
2018
23
Novel mutation (R192C) in CYB5R3 gene causing NADH-cytochrome b5 reductase deficiency in eight Indian patients associated with autosomal recessive congenital methemoglobinemia type-I. ( 29482478 )
2018
24
Autologous cervical fascia duraplasty in 123 children and adults with Chiari malformation type I: surgical technique and complications. ( 29932369 )
2018
25
The role of carboxy-terminal cross-linking telopeptide of type I collagen, dual x-ray absorptiometry bone strain and Romberg test in a new osteoporotic fracture risk evaluation: A proposal from an observational study. ( 29304151 )
2018
26
A points-based algorithm for prognosticating clinical outcome of Chiari malformation Type I with syringomyelia: results from a predictive model analysis of 82 surgically managed adult patients. ( 29125433 )
2018
27
Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers. ( 29975290 )
2018
28
Graded motor imagery for women at risk for developing type I CRPS following closed treatment of distal radius fractures: a randomized comparative effectiveness trial protocol. ( 29940926 )
2018
29
Case of punctate palmoplantar keratoderma type I treated with combination of low-dose oral acitretin and topical salicylic acid and steroid. ( 29500825 )
2018
30
Suppression of the toll-like receptor 7-dependent type I interferon production pathway by autophagy resulting from enterovirus 71 and coxsackievirus A16 infections facilitates their replication. ( 29052054 )
2018
31
Analyzing the feasibility of discriminating between collagen type I and II using polarization resolved second harmonic generation. ( 29971934 )
2018
32
Syringobulbia in pediatric patients with Chiari malformation type I. ( 29701558 )
2018
33
Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. ( 29945921 )
2018
34
Effects of Alpha-hydroxy-isocaproic acid upon Body Composition in a Type I Diabetic Patient with Muscle Atrophy - A Case Study. ( 29962922 )
2018
35
Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding. ( 29288958 )
2018
36
Metabolic Syndrome and Cardiovascular Risk Factors after Hematopoietic Cell Transplantation in Severe Mucopolysaccharidosis, Type I (Hurler Syndrome). ( 29409846 )
2018
37
Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement. ( 29520425 )
2018
38
Prenatal caffeine ingestion induces long-term alterations in scavenger receptor class B type I expression and glucocorticoid synthesis in adult male offspring rat adrenals. ( 29958987 )
2018
39
A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I. ( 29356944 )
2018
40
Evaluation of Soft Tissue Hypertrophy at the Retro-Odontoid Space in Patients with Chiari Malformation Type I on Magnetic Resonance Imaging. ( 29870844 )
2018
41
Germinal mosaicism of PAX3 mutation caused Waardenburg syndrome type I. ( 29287868 )
2018
42
Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. ( 29950839 )
2018
43
A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry. ( 29426546 )
2018
44
Neutrophils drive type-I interferon production and autoantibodies in Wiskott-Aldrich syndrome. ( 29447842 )
2018
45
Role of adipose tissue derived stem cells differentiated into insulin producing cells in the treatment of type I diabetes mellitus. ( 29452233 )
2018
46
Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: a systematic review. ( 29518460 )
2018
47
Fulminant Herpes Simplex Virus Type I Encephalitis Despite Maximal Medical Therapy. ( 29900087 )
2018
48
Erratum. The addition of duraplasty to posterior fossa decompression in the surgical treatment of pediatric Chiari malformation Type I: a systematic review and meta-analysis of surgical and performance outcomes. ( 29125448 )
2018
49
MCPIP1 is a positive regulator of type I interferons antiviral activity. ( 29545178 )
2018
50
Cardiac-Related Spinal Cord Tissue Motion at the Foramen Magnum is Increased in Patients with Type I Chiari Malformation and Decreases Postdecompression Surgery. ( 29733988 )
2018

Variations for Type I

Expression for Type I

Search GEO for disease gene expression data for Type I.

Pathways for Type I

Pathways related to Type I according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 ACVR1B ACVR1C KRT13 KRT14 KRT16 KRT17
2 12.31 KRT13 KRT17 KRT18 KRT19
3
Show member pathways
12.24 ACVR1 ACVR1B ACVR1C TGFBR1
4
Show member pathways
12.23 COL1A1 COL1A2 KRT13 KRT14 KRT16 KRT17
5
Show member pathways
12.18 ACVR1 ACVR1B IL1R1 TGFBR1
6
Show member pathways
12.01 KRT13 KRT14 KRT16 KRT17 KRT18 KRT19
7 11.81 IFNAR1 IFNAR2 IL1R1 TGFBR1
8 11.68 COL1A1 COL1A2 TGFBR1
9
Show member pathways
11.67 KRT13 KRT14 KRT16 KRT17 KRT18 KRT19
10 11.64 COL1A1 COL1A2 IL1R1
11 11.55 ACVR1 ACVR1B ACVR1C TGFBR1
12 11.2 COL1A1 COL1A2 PRKAR1A
13
Show member pathways
10.98 ACVR1 ACVRL1 TGFBR1

GO Terms for Type I

Cellular components related to Type I according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 9.54 KRT13 KRT14 KRT18
2 cell periphery GO:0071944 9.43 KRT17 KRT18 KRT19
3 intermediate filament GO:0005882 9.23 KRT13 KRT14 KRT16 KRT17 KRT18 KRT19
4 collagen type I trimer GO:0005584 9.16 COL1A1 COL1A2
5 activin receptor complex GO:0048179 9.13 ACVR1 ACVR1B ACVR1C
6 extracellular exosome GO:0070062 10.02 ACVR1B COL1A2 KRT13 KRT14 KRT16 KRT17

Biological processes related to Type I according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.98 ACVR1 ACVR1B ACVR1C ACVRL1 PIP5K1C PRKAR1A
2 cytokine-mediated signaling pathway GO:0019221 9.92 COL1A2 IFNAR1 IFNAR2 IL1R1
3 in utero embryonic development GO:0001701 9.84 ACVR1 ACVR1B ACVRL1 TGFBR1
4 epidermis development GO:0008544 9.78 KRT14 KRT16 KRT17
5 transforming growth factor beta receptor signaling pathway GO:0007179 9.76 ACVR1 ACVRL1 COL1A2 TGFBR1
6 peptidyl-threonine phosphorylation GO:0018107 9.73 ACVR1 ACVR1B TGFBR1
7 signal transduction by protein phosphorylation GO:0023014 9.72 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1
8 cellular response to transforming growth factor beta stimulus GO:0071560 9.7 ACVRL1 COL1A1 TGFBR1
9 collagen fibril organization GO:0030199 9.67 COL1A1 COL1A2 TGFBR1
10 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.67 ACVR1 ACVR1B ACVRL1 TGFBR1
11 hair follicle morphogenesis GO:0031069 9.65 KRT17 KRT25 KRT27
12 pharyngeal system development GO:0060037 9.62 ACVR1 TGFBR1
13 intermediate filament cytoskeleton organization GO:0045104 9.61 KRT16 KRT18
14 intermediate filament organization GO:0045109 9.6 KRT17 KRT25
15 endocardial cushion morphogenesis GO:0003203 9.59 ACVR1 ACVRL1
16 protein heterotrimerization GO:0070208 9.58 COL1A1 COL1A2
17 pathway-restricted SMAD protein phosphorylation GO:0060389 9.58 ACVR1 TGFBR1
18 hair cycle GO:0042633 9.58 KRT14 KRT16 KRT25
19 nodal signaling pathway GO:0038092 9.57 ACVR1B ACVR1C
20 activin receptor signaling pathway GO:0032924 9.56 ACVR1 ACVR1B ACVRL1 TGFBR1
21 keratinization GO:0031424 9.56 KRT13 KRT14 KRT16 KRT17 KRT18 KRT19
22 skin morphogenesis GO:0043589 9.55 COL1A1 COL1A2
23 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007178 9.55 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1
24 positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation GO:1905007 9.51 ACVR1 TGFBR1
25 cornification GO:0070268 9.23 KRT13 KRT14 KRT16 KRT17 KRT18 KRT19
26 protein phosphorylation GO:0006468 10.03 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1

Molecular functions related to Type I according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.96 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1
2 protein serine/threonine kinase activity GO:0004674 9.93 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1
3 structural molecule activity GO:0005198 9.85 KRT13 KRT16 KRT17 KRT18 KRT25 KRT27
4 structural constituent of cytoskeleton GO:0005200 9.81 KRT14 KRT16 KRT17 KRT19
5 protease binding GO:0002020 9.75 COL1A1 COL1A2 IL1R1
6 growth factor binding GO:0019838 9.71 ACVR1 ACVR1B ACVR1C TGFBR1
7 SMAD binding GO:0046332 9.65 ACVR1 ACVR1B ACVRL1 COL1A2 TGFBR1
8 transforming growth factor beta binding GO:0050431 9.63 ACVR1 ACVRL1 TGFBR1
9 activin binding GO:0048185 9.61 ACVR1 ACVR1B ACVRL1
10 platelet-derived growth factor binding GO:0048407 9.55 COL1A1 COL1A2
11 transforming growth factor beta-activated receptor activity GO:0005024 9.52 ACVRL1 TGFBR1
12 transforming growth factor beta receptor activity, type I GO:0005025 9.5 ACVR1 ACVRL1 TGFBR1
13 type I interferon receptor activity GO:0004905 9.49 IFNAR1 IFNAR2
14 activin receptor activity, type I GO:0016361 9.46 ACVR1 ACVR1B ACVR1C ACVRL1
15 obsolete signal transducer, downstream of receptor, with serine/threonine kinase activity GO:0004702 9.35 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1
16 transmembrane receptor protein serine/threonine kinase activity GO:0004675 9.02 ACVR1 ACVR1B ACVR1C ACVRL1 TGFBR1
17 protein binding GO:0005515 10.5 ACVR1 ACVR1B ACVRL1 COL1A1 COL1A2 IFNAR1
18 kinase activity GO:0016301 10.02 ACVR1 ACVR1B ACVR1C ACVRL1 PIP5K1C PRKAR1A

Sources for Type I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....